{ "schemaVersion": "deck-intelligence.v1", "id": "019dd923-622c-750b-8b9a-cb61f3b5c0ba", "slug": "bb36c74f657a", "title": "Pulse Biosciences (PLSE)", "subtitle": "White Diamond Research · 2025-05", "author": "White Diamond Research", "date": "2025-05-03 00:00:00", "pageCount": 13, "kind": "research-note", "orientation": "portrait", "aspectRatio": 0.77272725, "targetCompany": "Pulse Biosciences", "targetTicker": "PLSE", "document": { "id": "019dd923-622c-750b-8b9a-cb61f3b5c0ba", "slug": "bb36c74f657a", "title": "Pulse Biosciences (PLSE)", "rawTitle": "PLSE Report 6", "authorId": "61_White_Diamond_Research", "authorName": "White Diamond Research", "authorDisplay": "White Diamond Research", "kind": { "slug": "research-note", "label": "Research note" }, "sourceType": { "slug": "short_seller", "label": "Short seller" }, "fileName": "2025-07-PLSE-Report-6.pdf", "sourceUrl": "https://whitediamondresearch.com/", "sourceDate": "2025-05-03 00:00:00", "presentationDate": "2025-05-03 00:00:00", "ingestedAt": "2026-04-22 23:06:57+00", "status": "ready", "pageCount": 13, "orientation": "portrait", "aspectRatio": 0.77272725, "targetCompany": "Pulse Biosciences", "targetTicker": "PLSE", "metadata": { "local_root": "/tmp/legacy-images/bb36c74f657a", "activist_firm": "White Diamond Research", "origin_corpus": "contrarian", "extraction_seconds": 182.06610918045044 } }, "coverage": { "pageCount": 13, "pagesIndexed": 13, "pagesWithImages": 13, "pagesWithMetadata": 13, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 75, "chartCount": 0, "metricSlides": 0, "toolMatches": 5, "documentToolMatches": 2, "frameworkMatches": 4, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": true, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "evidence": "The document follows a narrative of presenting challenges and obstacles faced by Pulse Biosciences, with the goal of showing that the company is unlikely to overcome them.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:01:59.893877+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 2, "name": "Expose Contradiction", "beatId": "fcde8679-d26a-45e2-ad0b-301ddbdb4ca3", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 7, "name": "Preempt Rebuttal", "beatId": "c416d54e-d670-401f-92d4-f4dd508f0a11", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document preempts potential rebuttals by discussing Farapulse's prior research and its implications for Pulse Biosciences.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null, "categoryName": "Booker's 7 Plots", "categorySlug": "booker-s-7-plots" }, "from": 10, "name": "Villain Critique", "beatId": "17111959-043c-4444-914f-d47e7b87f2ca", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document critiques Pulse Biosciences' leadership and market claims, portraying them as weak and unstable.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 2, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null, "categoryName": "Logical Reasoning", "categorySlug": "logical-reasoning" }, "matchId": "1071288f-f643-4626-b233-d55a73d5a78a", "evidence": "The document presents a pattern of Pulse Biosciences' failure and weakness, including its history of failure and weak clinical results.", "position": 0, "objective": "To identify patterns in Pulse Biosciences' failure and weakness", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:02:00.042257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 11, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "1ef62e8b-adc1-441c-a66b-e6fcf4ca1475", "evidence": "The document implies that investors who do not take action to address Pulse Biosciences' challenges will suffer financial losses.", "position": 1, "objective": "To highlight the cost of inaction for investors", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:02:00.078667+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "CEO quote contradiction", "slug": "ceo-quote-contradiction", "status": "active", "bestFor": "When management credibility is the lever", "canonId": "019dd9e1-52e9-717f-8454-93e627563ed6", "version": 1, "bodyDocId": "019dd9a1-8296-720d-8f51-da76937f9415", "description": "You reproduce management's own words — verbatim, with source and date — and\nthen place them next to the outcome that contradicts them. The CEO built\nthe rope; you put it around their own neck.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "c6e1d454-7a9c-466d-b7fa-54fcdbb9dccc", "evidence": null, "pageRefs": null, "priority": null, "whenToUse": "When management credibility is the lever", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.209813+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Maximum credibility**: no adjective you could write is as damning as the\n target's own prior statement.\n- **No rebuttal path**: management can't argue they didn't say it.\n- **It forces accountability onto a person**, not an institution — even if\n you aren't explicitly naming a villain elsewhere.\n- **Reporters amplify it**. A CEO-quote-contradiction slide is quotable,\n which means it lands in WSJ/FT/Bloomberg coverage.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Villain naming", "slug": "villain-naming", "status": "active", "bestFor": "When governance or specific decisions are the core thesis", "canonId": "019dd9e1-55a4-74db-9314-0ced4cd46cd2", "version": 1, "bodyDocId": "019dd9a1-88f1-72ad-8f4e-56ec29d7b369", "description": "You identify a **specific person** responsible for the target's underperformance\nor the behaviour you want changed — and name them. Not \"management\" or \"the\nboard\". A named executive or director with a specific failure attributable to\nthem.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "document", "agents": null, "matchId": "8e5f559a-8e5c-43f9-867b-02853f6ef623", "evidence": "PLSE management — former CEOs Darrin Uecker, Kevin Danahy, Burke T. Barrett and current CEO Paul A. LaViolette", "pageRefs": null, "priority": null, "whenToUse": "When governance or specific decisions are the core thesis", "confidence": null, "extraction": { "at": "2026-04-29 12:07:50.209813+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": null, "whyItWorks": "- **Accountability needs a face.** Voters (shareholders, regulators,\n journalists) act faster against people than institutions.\n- **Credibility rises with specificity.** \"The CFO has repeatedly missed\n guidance\" > \"Management has missed guidance\".\n- It **pre-empts evasion**. An individual can be removed; an abstraction\n cannot.\n- It **forces the target to respond personally** — and their defensive\n response usually generates more attention for your thesis.", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1f72ff98-4d69-40db-a75e-ec2cfaf61217", "evidence": "This slide provides a summary of Pulse Biosciences' history of failure.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:48.84676+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2b22f812-ba54-44cf-85f9-37983fc34f34", "evidence": "This slide provides a summary of the market for thyroid ablation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:49.209247+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7164b58e-3007-4ad6-be9e-97cf8c9cf0d4", "evidence": "This slide contains a summary of the key points, making it an executive summary.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:38.571061+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0bc45958-59e7-4553-baa6-996b9d1c2b56", "evidence": "Contrasting two quotes from the same expert to highlight a discrepancy in product quality perception.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "expose_contradiction" }, { "matchId": "25f1b4f8-53a0-4b90-8980-58a800bf959c", "evidence": "The slide explicitly challenges the bullish thesis on PLSE by citing the actions of a market leader (Farapulse) to invalidate the technology's potential.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "preempt_rebuttal" }, { "matchId": "63198f9c-9406-4220-bcca-2a060fff4ebc", "evidence": "The slide explicitly frames the company's claims as 'mediocre' and 'laughable' to discredit them.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "villain_critique" }, { "matchId": "33d42605-2f5d-4f22-b553-349a0efe6000", "evidence": "The slide systematically attacks the company's market claims and management stability to cast doubt on its valuation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "fraud-exposure" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": { "tone": "adversarial", "notes": "Short-seller research note from White Diamond Research (document #6 in their PLSE series, hence follow_up). Cover date is 03 May 2025; filename prefix '2025-07' conflicts but cover is authoritative. No named individual author — firm-authored. Core rhetorical move: using PLSE's own paid consultant Dr. Vivek Reddy's public statements to undercut PLSE's cardiac-PFA differentiation. No formal valuation or price target; no charts or data visualizations (prose-heavy report with one embedded screenshot on p5). Thesis type choice: 'multiple_rerating' for the overvaluation-will-correct argument, 'management_change' given the heavy CEO-churn section, 'other' to capture the implicit commercial-failure / tech-won't-work thesis that doesn't cleanly map to the enum. Not fraud_exposure — no accounting or accusation of outright deception, though tone accuses management of 'BSing shareholders'.", "kpisCited": [ { "detail": "83% — vs 95.7% at 5 years for RF ablation and 98.8% at 10 years", "metric": "Thyroid volume reduction at 1 year (PLSE, n=3)" }, { "detail": "$50M+ per year", "metric": "Annual cash burn" }, { "detail": "$1B+ on no material revenue in 20 years", "metric": "Market cap" }, { "detail": "3 CEOs in 3 years (Uecker → Danahy → Barrett → LaViolette)", "metric": "CEO turnover" }, { "detail": "Fell from $45 to below $1 when dermatology application failed", "metric": "2021 stock drawdown" }, { "detail": "~100,000; RF thyroid ablation TAM only ~$10-20M", "metric": "US benign thyroid surgeries per year" }, { "detail": "~$500M by Boston Scientific in 2021", "metric": "Farapulse acquisition price" }, { "detail": "~$50M in 2024 after 20 years of clinical research", "metric": "Nanoknife revenue (AngioDynamics proxy for IRE)" } ], "closingAsk": "Given PLSE's weak initial clinical data in thyroids, we predict a forthcoming commercial failure inevitably leading to another stock crash like 2021's dermatology collapse.", "extraction": { "at": "2026-04-22 23:06:57+00", "model": "unknown-legacy", "runId": null, "seconds": 182.06612, "promptVersion": null }, "scqaReward": "Expect another stock collapse comparable to 2021, when PLSE fell from $45 to below $1 in a single year after its dermatology application unraveled.", "thesisTypes": [ "multiple_rerating", "management_change", "other" ], "top3Reasons": [ "PLSE's own paid consultant Dr. Vivek Reddy states nano-second PFA has no advantage over micro-second PFA", "Benign thyroid ablation market is only $10-20M and PLSE's early data (83% reduction) trails RF ablation (95.7%)", "Three CEOs have departed in three years, echoing the 2021 dermatology collapse from $45 to below $1" ], "scqaSituation": "Pulse Biosciences is a speculative MedTech with a $1B+ market cap and no material revenue in twenty years, having failed in oncology and dermatology before pivoting to cardiac PFA in 2022.", "thesisSummary": "White Diamond Research argues Pulse Biosciences (PLSE), a $1B+ market-cap MedTech with no material revenue in twenty years, will crash as its third pivot — benign thyroid ablation — fails like its earlier dermatology and cardiac PFA attempts. PLSE's own paid consultant Dr. Vivek Reddy publicly stated nano-second PFA offers no advantage over micro-second PFA for atrial ablation, undercutting the cardiac thesis. Farapulse, acquired by Boston Scientific for $500M in 2021, had already tested and abandoned nano-second PFA years earlier, while JNJ, Abbott, and Kardium race ahead in PFA. The new thyroid market is only $10-20M, dominated by RF ablation, and PLSE's first 30-patient study showed only 83% volume reduction at one year versus 95.7% at five years for RF. Three CEOs have departed in three years without explanation. Expect a repeat of the 2021 crash from $45 to below $1.", "primaryDemands": [ "Avoid or short PLSE ahead of anticipated commercial failure in benign thyroid ablation" ], "scqaResolution": "Sell or short PLSE; the thyroid story is a reprise of the 2020 dermatology pitch, and weak 83% volume-reduction data plus three CEO departures in three years signal imminent commercial failure.", "thesisOneLiner": "PLSE's pivot to benign thyroid ablation repeats its failed dermatology playbook — tiny market, weak clinical data, revolving-door CEOs — and will trigger another stock collapse.", "precedentsCited": [ "PLSE 2021 dermatology collapse ($45 to below $1)", "Farapulse abandonment of nano-second PFA (acquired by Boston Scientific for $500M in 2021)", "Nanoknife / AngioDynamics (IRE) — 20 years, ~$50M revenue, commercially underwhelming" ], "scqaComplication": "Cardiac PFA has stalled — Farapulse, JNJ, Abbott and Kardium are far ahead, and PLSE's own paid consultant admits nano-second offers no real advantage — so PLSE is pivoting again to benign thyroid ablation, a tiny market with weak early data.", "narrativeInterest": 3, "notableSlidePages": [ 1, 4, 11, 12 ], "peerCompaniesCited": [ "Farapulse / Boston Scientific", "Johnson & Johnson / Biosense Webster", "Abbott", "Medtronic", "Kardium", "Adagio Medical", "AngioDynamics (Nanoknife / IRE)" ], "valuationFrameworks": [ "precedent_transactions", "multiple_comparison" ], "visualCraftInterest": 2 }, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "analysis", "title": "The slide uses a skeptical, investigative tone to frame the company's history as a series of failures.", "function": "diagnose_problem", "imagePath": "https://imgproxy.kitesheet.com/wN3kwbFD-kmjFgPpHReuvukEViBBLIM1sQABJ6egqQg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iYjM2Yzc0ZjY1N2EvcDAwMS5wbmc", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 12, "textChars": 2045, "nDataPoints": 0, "notes": "The slide uses a skeptical, investigative tone to frame the company's history as a series of failures.", "elementsJson": [ "headline_text", "bullet_list", "paragraph", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:58.605+00", "seconds": 3.843, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/1", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-1", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Pulse Biosciences History Of Failure Will Likely Continue", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8662-e22d08858c24", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.45 }, "kind": "list", "text": "PLSE’s own paid consultant and investigator of trials, Dr. Vivek Reddy, who owns stock/options in PLSE, has stated that there’s likely no benefit with nano-pulse PFA over micro-pulse PFA. And if there is any benefit, it would be a niche one but that “still remains to be proven”.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0db01b7c-1e7a-458b-b584-604753fcb45a", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.9, "x": 0.05, "y": 0.54 }, "kind": "list", "text": "Early PLSE clinical data on thyroids are of poor quality and the outcomes suggest inferior performance vs the competition.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69e3025b-4caa-42c8-8c3a-8521526bb1b7", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.38 }, "kind": "list", "text": "Today, 3-years later, the company has made little progress in developing its technology for the PFA market and is making another transition to Benign Thyroid Ablation. This market is small, and looks to be another dead end for PLSE.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0ee7087-50b5-4718-bc9f-7f38c5d8f59d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.29 }, "kind": "list", "text": "Pulse Biosciences (PLSE) started in 2004 with its Nano-Pulse Stimulation (NPS) technology, and hasn’t found any success in over 20 years. It failed its dermatology application in 2021, then abandoned it and went into the Pulsed Field Ablation (PFA) cardiac market in 2022.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb592be2-3777-42ee-8be7-07e7f627b93e", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.9, "x": 0.05, "y": 0.59 }, "kind": "list", "text": "PLSE has lost three CEOs over the past three years, and the company doesn’t say why. We logically speculate the reasons.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "de4cffd1-6185-4a8c-aa56-ae7df2e61bf2", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.71 }, "kind": "paragraph", "text": "Pulse Biosciences (PLSE) is a speculative MedTech company that has not made any material revenue over the past 20 years with their Nano-Pulse Stimulation (NPS) technology. They started in the oncology field, then pivoted to dermatology. As stated from a Google search:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6535c858-cb70-422f-8398-178815fdbafc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.79 }, "kind": "paragraph", "text": "In 2004, Pulse Biosciences was focused on developing and commercializing medical devices for ablative treatments, particularly in the oncology field. The company was developing its proprietary Nano-Pulse Stimulation (NPS) technology, which would later become the foundation for its CellFX System. The CellFX System is used for dermatologic conditions, leveraging the non-thermal nature of NPS to address areas where traditional solutions are limited.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3cfeef3-3e84-4272-970e-fd478f6cac7d", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "“still remains to be proven” — Dr. Vivek Reddy", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8662-e7df21191d03", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.1, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Source: Google", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2c64303-c64f-4dba-99f0-ad54c6469b98", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.66 }, "kind": "title", "text": "Pulse Biosciences History Of Failure Will Likely Continue", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c8e9c886-c831-4f5a-a78a-65722698f9d8", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.21 }, "kind": "title", "text": "An Industry Expert’s Analysis of Pulse Biosciences Suggests That Its Pivot Into Benign Thyroid Ablation Will Be Another Dead End", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.605+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2df435d-c50b-4945-b7cf-14a3163a5a32", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1f72ff98-4d69-40db-a75e-ec2cfaf61217", "evidence": "This slide provides a summary of Pulse Biosciences' history of failure.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:48.84676+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/_i_yJJ5AMGqwuK3bg_lwu-Zl9ezvuT0S5ODNpxQx8F0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iYjM2Yzc0ZjY1N2EvcDAwMS5wbmc", "imagePathAlt": "https://imgproxy.kitesheet.com/vnMmu5GaFNK4y_MhI8uf3EEGvQz4FpGdYyLPTgQDQLw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iYjM2Yzc0ZjY1N2EvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/GjVi5QycQWlGckJ9zJaMSJYUNNJMJg5n4qP5DaRtWG0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iYjM2Yzc0ZjY1N2EvcDAwMS5qcGc" }, { "page": 2, "type": "tension", "title": "The slide uses a 'compare and contrast' rhetorical strategy to undermine the credibility of PLSE's technology by highlighting a more favorable endorsement given", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 8, "textChars": 1736, "nDataPoints": 0, "notes": "The slide uses a 'compare and contrast' rhetorical strategy to undermine the credibility of PLSE's technology by highlighting a more favorable endorsement given to a competitor by a shared consultant.", "elementsJson": [ "paragraph", "headline_text" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:09:02.587+00", "seconds": 7.787, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/2", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-2", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Dr. Vivek Reddy is one of the nation's premier cardiac electrophysiologists. He is a consultant for many companies in the PFA field, including PLSE and Kardium. His statement above about Kardium is a lot stronger than what he said regarding PLSE.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8662-fe06d0004409", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.08, "y": 0.32 }, "kind": "paragraph", "text": "Kardium is a private company that, like PLSE, is developing a catheter system for PFA. However, unlike PLSE, Kardium has some real innovation. Its Globe PF System is their catheter, much more advanced than PLSE's basic catheter.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "275ef194-e2a7-4808-944b-d565f70423a2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.08, "y": 0.15 }, "kind": "paragraph", "text": "18 years later, in 2022, PLSE realized that their NPS technology wasn't marketable to treat dermatology conditions. It then pivoted to a new field that was booming – Pulsed Field Ablation (PFA) in cardiac applications.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "755237bf-1a14-4a9a-983c-c73749fd30c5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.08, "y": 0.52 }, "kind": "quote", "text": "These impressive one-year efficacy results underscore the advanced catheter design of the Globe PF System... Given the excellent durability achieved by the Globe PF System, the efficacy result is likely approaching the limit of what we can achieve with PV isolation alone.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18d20360-b5f3-40a7-aaad-7d17e37ed7c9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.08, "y": 0.75 }, "kind": "quote", "text": "The remap results for the first 30 patients treated with the Nanosecond PFA 360° Cardiac Catheter demonstrate strong pulmonary vein isolation (PVI) with short case times... This novel technology offers a unique user experience that has the potential to improve workflow...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69f60f96-ddac-40f1-817f-d0a39fc2ed40", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "\"These impressive one-year efficacy results underscore the advanced catheter design of the Globe PF System,\" said Dr. Vivek Reddy, Co-Principal Investigator from The Mount Sinai Fuster Heart Hospital, New York. \"Given the excellent durability achieved by the Globe PF System, the efficacy result is likely approaching the limit of what we can achieve with PV isolation alone.\" — Dr. Vivek Reddy", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-0125f7a4fde1", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.1, "x": 0.08, "y": 0.12 }, "kind": "source-note", "text": "Source: Google", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b074647-cdad-4441-bda3-2f82a36098b5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.25 }, "kind": "title", "text": "Pulse Biosciences Competitor Kardium Recently Announced Stellar Results for Its PFA Catheter", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82918a76-cddd-405e-9c94-01d6e2761277", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0bc45958-59e7-4553-baa6-996b9d1c2b56", "evidence": "Contrasting two quotes from the same expert to highlight a discrepancy in product quality perception.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:02.587+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "expose_contradiction" } ], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "Expose Contradiction", "beatId": "fcde8679-d26a-45e2-ad0b-301ddbdb4ca3", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 2, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "1071288f-f643-4626-b233-d55a73d5a78a", "evidence": "The document presents a pattern of Pulse Biosciences' failure and weakness, including its history of failure and weak clinical results.", "position": 0, "objective": "To identify patterns in Pulse Biosciences' failure and weakness", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:02:00.042257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 3, "type": "tension", "title": "This appears to be a snippet from a larger research report by White Diamond Research, focusing on critical analysis of company claims.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "sparse", "densityScore": 15, "componentCount": 4, "textChars": 410, "nDataPoints": 0, "notes": "This appears to be a snippet from a larger research report by White Diamond Research, focusing on critical analysis of company claims.", "elementsJson": [ "paragraph", "logo_grid" ], "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:57.253+00", "seconds": 2.435, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/3", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-3", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "His tone is neutral at best in regards to the PLSE 360° Catheter’s limitations.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-1333b6f124c5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.23, "x": 0.08, "y": 0.06 }, "kind": "image", "text": "WHITE DIAMOND RESEARCH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a1c0fa5-ade8-4488-b255-3ef53d33c6b5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.84, "x": 0.08, "y": 0.13 }, "kind": "paragraph", "text": "For PLSE, he says “potential to improve workflow with a pliable catheter”, not mentioning that PLSE’s Nanosecond PFA 360° Cardiac Catheter is anything special. His tone is neutral at best in regards to the PLSE 360° Catheter’s limitations.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.253+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9799bca4-3586-4952-a517-bfb307ad0077", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "potential to improve workflow with a pliable catheter — Unnamed Expert", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-148537ff71a4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "Expose Contradiction", "beatId": "fcde8679-d26a-45e2-ad0b-301ddbdb4ca3", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 2, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "1071288f-f643-4626-b233-d55a73d5a78a", "evidence": "The document presents a pattern of Pulse Biosciences' failure and weakness, including its history of failure and weak clinical results.", "position": 0, "objective": "To identify patterns in Pulse Biosciences' failure and weakness", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:02:00.042257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "setup", "function": "front_matter", "rawType": "table_of_contents", "block": null, "metadata": { "slideType": "table_of_contents", "slideTypeCanon": { "name": "Table of contents", "slug": "table_of_contents", "status": "active", "canonId": "019de52d-0643-721b-9b85-69676bb85cf8", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 3, "textChars": 918, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:57.805+00", "seconds": 2.739, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/4", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-4", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.03, "x": 0.93, "y": 0.23 }, "kind": "list", "text": "01\n01\n02\n05\n07\n08\n08\n10\n10\n11\n12", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "268dca3a-8c8a-437a-90da-c0dc39d28711", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.8, "x": 0.07, "y": 0.18 }, "kind": "list", "text": "An Industry Expert’s Analysis of Pulse Biosciences Suggests That Its Pivot Into Benign Thyroid Ablation Will Be Another Dead End\nPulse Biosciences History Of Failure Will Likely Continue\nPulse Biosciences Competitor Kardium Recently Announced Stellar Results for Its PFA Catheter\nDr. Vivek Reddy, Pulse’s Own Hired Consultant, States There Isn’t An Advantage To Using Nano-second PFA Compared to Micro-Second PFA For Most Procedures\nFarapulse Has Already Studied Nano-Pulse Technology for Pulsed Field Ablation Years Before Pulse Biosciences Did\nA Look At Pulse Biosciences Tough Competition in the Pulsed Field Ablation Space\nA Look At The Benign Thyroid Ablation Field\nPulse’s Early Clinical Results For Thryoid Ablation Are Weak\nThe Benign Thryoid Ablation Market Is Small\nPulse Has Lost 3 CEOs Over the Past 3 Years, And Hasn’t Explained The Reasons Why\nConclusion", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b27d622c-cfe9-4eef-afde-4a2d91ed0dcf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "Tables of contents", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.805+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe74567c-99f5-42ed-b66c-162495ab3a3b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "Expose Contradiction", "beatId": "fcde8679-d26a-45e2-ad0b-301ddbdb4ca3", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 2, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "1071288f-f643-4626-b233-d55a73d5a78a", "evidence": "The document presents a pattern of Pulse Biosciences' failure and weakness, including its history of failure and weak clinical results.", "position": 0, "objective": "To identify patterns in Pulse Biosciences' failure and weakness", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:02:00.042257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "tension", "title": "The slide uses a screenshot of a technical presentation to undermine the company's technological claims.", "function": "expose_contradiction", "rawType": "expose_contradiction", "block": null, "metadata": { "slideType": "expose_contradiction", "slideTypeCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-124c-75aa-984a-0a3d0d8fc8df", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 7, "textChars": 1507, "nDataPoints": 0, "notes": "The slide uses a screenshot of a technical presentation to undermine the company's technological claims.", "elementsJson": [ "headline_text", "paragraph", "screenshot", "footnote" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:09:01.869+00", "seconds": 6.507, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/5", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-5", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Dr. Vivek Reddy, Pulse’s Own Hired Consultant, States There Isn’t An Advantage To Using Nano-second PFA Compared to Micro-Second PFA For Most Procedures", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-4ecb74cc7a71", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.58, "x": 0.21, "y": 0.36 }, "kind": "image", "text": "Screenshot of Dr. Reddy's presentation slide detailing the Nanosecond PFA Catheter.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:01.869+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2036bee5-f3b7-439d-8cc8-e7b195299977", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.85, "x": 0.08, "y": 0.68 }, "kind": "paragraph", "text": "PLSE’s catheter is far from being approved for commercial use. It lacks magnetic sensors and isn’t an over-the-wire system. The lack of magnetic sensors prevents it from using standard magnetic mapping. Instead, electrical impedance mapping was used, which positions the catheter inaccurately; ICE catheter and fluoro imaging had to be used to verify the catheter position.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:01.869+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10f3684a-4f83-4997-a257-780129cba1ee", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.85, "x": 0.08, "y": 0.23 }, "kind": "paragraph", "text": "Dr. Vivek Reddy did a presentation at the 29th Annual International Atrial Fibrillation Symposium, showcasing his work on PLSE’s feasibility study. This was in February 2024. At the :21 time mark, Dr. Reddy discloses that he has an equity stake/stock options in PLSE, Kardium, and a slew of other MedTech companies in the PFA field.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:01.869+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7dab6eeb-2471-4c5f-aa27-af579842f20e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.85, "x": 0.08, "y": 0.78 }, "kind": "paragraph", "text": "Because the Catheter 360 is not an Over-the-Wire system, its application is limited to a regional ablation according to Dr. Reddy.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:01.869+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2a98c52-de07-4ba0-90b3-fabe1c79f75c", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Ed: Just a quick question. If you can comment, since we have a lot of data with micro-second pulse field ablation, what are the theoretical benefits to nano-second? Is there less skeletal muscle stimulation or what’s the potential advantage? — Ed (Audience Member at AF Symposium 2024)", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-50439aadef31", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.08, "y": 0.14 }, "kind": "title", "text": "Dr. Vivek Reddy, Pulse’s Own Hired Consultant, States There Isn’t An Advantage To Using Nano-second PFA Compared to Micro-Second PFA For Most Procedures", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:01.869+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dac5dfd8-99ac-46a6-ab84-14510c3efe35", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 2, "name": "Expose Contradiction", "beatId": "fcde8679-d26a-45e2-ad0b-301ddbdb4ca3", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 5, "from": 2, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "1071288f-f643-4626-b233-d55a73d5a78a", "evidence": "The document presents a pattern of Pulse Biosciences' failure and weakness, including its history of failure and weak clinical results.", "position": 0, "objective": "To identify patterns in Pulse Biosciences' failure and weakness", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:02:00.042257+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "appendix", "title": "The slide presents a transcript excerpt followed by an analyst's interpretation of the expert's (Dr. Reddy) views on PFA pulse duration.", "function": "summarize", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 4, "textChars": 609, "nDataPoints": 0, "notes": "The slide presents a transcript excerpt followed by an analyst's interpretation of the expert's (Dr. Reddy) views on PFA pulse duration.", "elementsJson": [ "paragraph", "quote_block" ], "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:57.751+00", "seconds": 2.141, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/6", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-6", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "We interpret this to mean that with PFA in the atrium, both micro-second and nano-second work, there's no big advantage to one over the other.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-68e0b5d46758", "parentComponentId": null }, { "bbox": { "x": 0.08, "y": 0.07 }, "kind": "image", "text": "WHITE DIAMOND RESEARCH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.751+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69ecfd97-73b2-4050-9564-5f4feba80186", "parentComponentId": null }, { "bbox": { "x": 0.08, "y": 0.14 }, "kind": "paragraph", "text": "Transcript of an interview with Dr. Reddy discussing the technical and clinical differences between micro-second and nano-second PFA pulses, followed by analyst commentary.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:57.751+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6bcf57f-4222-492e-8ad4-67939c8d6a60", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "we've been talking about the atrium, for which I think micro-second, nano-second both would be OK. But when we get into the ventrical, there are reasons to think that the nano-second would be able to make deeper lesions. So, again this still needs to be proven. — Dr. Reddy", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-6cdf63c49acd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "title": "Includes an AI-generated summary box at the top and specific patent quote excerpts to support the argument.", "function": "preempt_rebuttal", "rawType": "preempt_rebuttal", "block": null, "metadata": { "slideType": "preempt_rebuttal", "slideTypeCanon": { "name": "Preempt rebuttal", "slug": "preempt_rebuttal", "status": "active", "canonId": "019de52d-1225-7368-af32-6381fddabdb3", "version": 1, "description": null }, "function": "preempt_rebuttal", "functionCanon": { "name": "Preempt rebuttal", "slug": "preempt_rebuttal", "status": "active", "canonId": "019de52d-18ab-7479-9a7e-820a2f03586a", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 9, "textChars": 1415, "nDataPoints": 1, "notes": "Includes an AI-generated summary box at the top and specific patent quote excerpts to support the argument.", "elementsJson": [ "paragraph", "callout_box" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:09:03.679+00", "seconds": 8.026, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/7", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-7", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.6, "x": 0.24, "y": 0.09 }, "kind": "callout", "text": "While pulsed field ablation (PFA) is primarily known for its use in atrial fibrillation (AFib) treatment, it's also being explored for ventricular arrhythmias.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4dd2c1d0-1685-4d14-a213-9863ae1d450e", "parentComponentId": null }, { "bbox": null, "kind": "callout", "text": "It's clear that Farapulse had done thorough diligence and experimentation, and decided that micro-second PFA is better than nano-second PFA.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-912df477254e", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.85, "x": 0.08, "y": 0.65 }, "kind": "list", "text": "“In some embodiments, the pulse time duration of each biphasic pulse is in the range from about 0.5 nanosecond to about 20 microseconds.”", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa89869b-2823-4fad-a6d6-b608bd56ba62", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "cash burn: $50M+", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-9b838eca830d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.81 }, "kind": "paragraph", "text": "It’s clear that Farapulse had done thorough diligence and experimentation, and decided that micro-second PFA is better than nano-second PFA. Otherwise, there is nothing stopping them from going the nano-second route.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6aaa70f6-b927-4299-b0d8-cbe286c87a0a", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.85, "x": 0.08, "y": 0.47 }, "kind": "paragraph", "text": "Farapulse is the market leader in PFA and was acquired by Boston Scientific (BSX) in 2021 for about $500M. It had already been studying nano-second PFA for years before PLSE was ever involved in PFA and before PLSE had any patents for it.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97e4f755-c5dd-4a6e-b9a9-38a9ad8bc6ed", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.08, "y": 0.27 }, "kind": "paragraph", "text": "Dr. Reddy claimed “time will tell” if nano-second PFA has any advantages. This presentation was over a year ago. We’ve looked at Dr. Reddy’s public statements since then and we haven’t seen him change his tune on nano-second PFA.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5dbb9d6-38ab-436c-a96d-5128ff8a1514", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "\"In some embodiments, the pulse time duration of each biphasic pulse is in the range from about 0.5 nanosecond to about 20 microseconds.\" — Farapulse Patent Description", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-9703810d16aa", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.41 }, "kind": "title", "text": "Farapulse Has Already Studied Nano-Pulse Technology for Pulsed Field Ablation Years Before Pulse Biosciences Did", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20d4c037-2cb8-4e8d-8dcb-3a90c77d3d01", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "25f1b4f8-53a0-4b90-8980-58a800bf959c", "evidence": "The slide explicitly challenges the bullish thesis on PLSE by citing the actions of a market leader (Farapulse) to invalidate the technology's potential.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:03.679+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "preempt_rebuttal" } ], "arcBeats": [ { "to": 7, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 7, "name": "Preempt Rebuttal", "beatId": "c416d54e-d670-401f-92d4-f4dd508f0a11", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document preempts potential rebuttals by discussing Farapulse's prior research and its implications for Pulse Biosciences.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "setup", "title": "The slide contrasts the competitive PFA market with the alternative focus on thyroid ablation.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 5, "textChars": 633, "nDataPoints": 0, "notes": "The slide contrasts the competitive PFA market with the alternative focus on thyroid ablation.", "elementsJson": [ "headline_text", "bullet_list", "paragraph" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:59.117+00", "seconds": 3.17, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/8", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-8", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "With growing competition strength and the lackluster progress with its own Electrophysiology catheter program, PLSE has to find another thing to keep investors engaged. And it is benign thyroid ablation today!", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:28+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-290ac289468a", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.85, "x": 0.08, "y": 0.13 }, "kind": "list", "text": "JNJ/Biosense Webster, Abbott, Kardium, and Adagio Medical are highlighted as competitors with more advanced PFA development stages.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ab2da4e-462a-46c7-bf26-a785c861e9b5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.08, "y": 0.79 }, "kind": "paragraph", "text": "Thyroid ablation has been done using multiple ablation modalities. Overall, ultrasound-guided ablation procedures offer some advantages compared with traditional surgery.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b9d8b69-4e47-4eed-93ec-607b34745209", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.08, "y": 0.75 }, "kind": "title", "text": "A Look At The Benign Thyroid Ablation Field", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05756bc6-ecb3-4768-8593-13a98f2f1b91", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.07 }, "kind": "title", "text": "A Look At Pulse Biosciences Tough Competition in the Pulsed Field Ablation Space", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.117+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93ea6d45-e33a-47b4-8c26-7685665b6a96", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "The slide provides a critical assessment of IRE technology, specifically referencing Nanoknife and AngioDynamics' financial performance to argue against its mar", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 3, "textChars": 483, "nDataPoints": 4, "notes": "The slide provides a critical assessment of IRE technology, specifically referencing Nanoknife and AngioDynamics' financial performance to argue against its market potential.", "elementsJson": [ "paragraph", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:58.006+00", "seconds": 1.957, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/9", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-9", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Our conclusion is the market is not excited by the future of IRE technology in ablative soft tissue applications.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:29+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-7e82855f6ced", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.105, "y": 0.075 }, "kind": "image", "text": "WHITE DIAMOND RESEARCH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e71edfa4-aeea-4919-a763-fcceb4c3c2a0", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.79, "x": 0.105, "y": 0.15 }, "kind": "paragraph", "text": "Overall, ablation is not as good as surgery in achieving and maintaining euthyroidism... RF ablation is a dominant technology for thyroid ablation... Laser ablation is also popular... IRE (Irreversible Electroporation) technology is the same technology as ms-PFA... One of the most popular devices for IRE ablation of cancers/tumors is Nanoknife...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6e6fc28-7fd7-449c-964d-91a0fb220d44", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2b22f812-ba54-44cf-85f9-37983fc34f34", "evidence": "This slide provides a summary of the market for thyroid ablation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:49.209247+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 10, "type": "tension", "title": "The slide uses a 'villain_critique' approach to undermine the company's clinical claims and market potential.", "function": "expose_contradiction", "rawType": "villain_critique", "block": null, "metadata": { "slideType": "villain_critique", "slideTypeCanon": { "name": "Villain critique", "slug": "villain_critique", "status": "active", "canonId": "019de52d-10bc-7136-bf20-09de59d17447", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 8, "textChars": 1361, "nDataPoints": 12, "notes": "The slide uses a 'villain_critique' approach to undermine the company's clinical claims and market potential.", "elementsJson": [ "paragraph", "quote_block" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:58.962+00", "seconds": 2.896, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/10", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-10", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "To call this clinical outcome impressive, to our mind, is laughable.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:30+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-e653fc5df918", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.84, "x": 0.08, "y": 0.56 }, "kind": "paragraph", "text": "It looks like PLSE’s CEO is trying to promote very mediocre data on thyroids. Indeed, the CEO talks about a selected 3 patients from the group of 30 included in the study...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2417d029-0831-4f60-9e35-d28b0d12d0e2", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.84, "x": 0.08, "y": 0.85 }, "kind": "paragraph", "text": "It seems that the total number of thyroid surgeries in the US, quoted in this 2022 paper, is approximately 140,000 per year...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a142ef14-218a-426d-ae4f-9571887d685d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.84, "x": 0.08, "y": 0.14 }, "kind": "paragraph", "text": "Note: AngioDynamics does not report direct sales from Nanoknife. We traced the estimation by analyzing Q1 reports from 2021 to 2025...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7421478-ad48-4232-8c9b-2c983664be55", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.84, "x": 0.08, "y": 0.41 }, "kind": "quote", "text": "We are very pleased by the quality of the preliminary data from our First-In-Human Feasibility Study conducted in Italy...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Pull quote", "slug": "pull-quote", "status": "active", "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9", "version": 1, "description": null }, "framework": null }, "subkind": "pull-quote", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb244e71-c765-440d-8fcf-0209ca4eddc3", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "We are very pleased by the quality of the preliminary data from our First-In-Human Feasibility Study conducted in Italy and presented at the American Thyroid Association 2024 Annual Meeting. The data presented on 30 patients in three distinct cohorts demonstrated our system's effectiveness in reducing nodule size. In Cohort 3, three patients received complete nodule treatment and achieved on average 83% volume reduction at one year and significant reductions in symptoms just one month after treatment without evidence of residual fibrosis or scarring that would routinely accompany radiofrequency ablation. — Pulse Biosciences CEO", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:30+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-eb2ec15e85bc", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.84, "x": 0.08, "y": 0.31 }, "kind": "title", "text": "Pulse’s Early Clinical Results For Thryoid Ablation Are Weak", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86b239f7-3e62-40ad-8293-dc36bf1fbc5e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.84, "x": 0.08, "y": 0.81 }, "kind": "title", "text": "The Benign Thryoid Ablation Market Is Small", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdf585f7-4e55-4cae-9103-07f7272edd33", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "63198f9c-9406-4220-bcca-2a060fff4ebc", "evidence": "The slide explicitly frames the company's claims as 'mediocre' and 'laughable' to discredit them.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:08:58.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "villain_critique" } ], "arcBeats": [ { "to": 11, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 10, "name": "Villain Critique", "beatId": "17111959-043c-4444-914f-d47e7b87f2ca", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document critiques Pulse Biosciences' leadership and market claims, portraying them as weak and unstable.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1ef62e8b-adc1-441c-a66b-e6fcf4ca1475", "evidence": "The document implies that investors who do not take action to address Pulse Biosciences' challenges will suffer financial losses.", "position": 1, "objective": "To highlight the cost of inaction for investors", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:02:00.078667+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "tension", "title": "The slide uses a 'villain critique' approach to undermine the credibility of the company's management and market opportunity claims.", "function": "expose_contradiction", "rawType": "villain_critique", "block": null, "metadata": { "slideType": "villain_critique", "slideTypeCanon": { "name": "Villain critique", "slug": "villain_critique", "status": "active", "canonId": "019de52d-10bc-7136-bf20-09de59d17447", "version": 1, "description": null }, "function": "expose_contradiction", "functionCanon": { "name": "Expose contradiction", "slug": "expose_contradiction", "status": "active", "canonId": "019de52d-171f-776f-887c-73edaff4cf9c", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 5, "textChars": 900, "nDataPoints": 6, "notes": "The slide uses a 'villain critique' approach to undermine the credibility of the company's management and market opportunity claims.", "elementsJson": [ "paragraph", "numbered_list", "headline_text" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:09:02.588+00", "seconds": 6.495, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/11", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-11", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "PLSE doesn't explain this weird rotating door for CEOs. But we can logically speculate what is going on.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:33+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8665-a235621e9427", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.85, "x": 0.08, "y": 0.605 }, "kind": "list", "text": "On 9/20/22, PLSE announced Kevin Danahy was appointed as new CEO.\nOn 5/14/24, PLSE announced Burke T. Barrett has been appointed CEO.\nOn 12/6/24 PLSE announced the resignation of its CEO, Burke T. Barrett.\nOn 1/10/25, PLSE announced the appointment of Paul A. LaViolette as CEO.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b7ec5a3-f6ad-4a95-9151-5020de19f024", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.08, "y": 0.355 }, "kind": "list", "text": "1. PLSE prior 2021 failure in the creation of an Untapped Market in Dermatology\n2. PLSE's lack of reimbursement code in Thyroids vs existing CPT code for RF ablation\n3. PLSE's initial 3 patients' data on thyroid volume reduction of 83%", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74dc55d6-0746-418e-9067-c9ea2c6d3928", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.08, "y": 0.145 }, "kind": "paragraph", "text": "Medtronic is a major player providing RF ablation technologies for soft tissue ablation. It is interesting that Medtronic does not even mention RF ablation as an option in its info section for thyroids.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56f6a5fc-59d8-41e4-8a40-6f98c92f3b15", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.545 }, "kind": "title", "text": "Pulse Has Lost 3 CEOs Over the Past 3 Years, And Hasn't Explained The Reasons Why", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b68a41e-7e7a-4f5c-b4ca-e3c872245399", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "33d42605-2f5d-4f22-b553-349a0efe6000", "evidence": "The slide systematically attacks the company's market claims and management stability to cast doubt on its valuation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 20:09:02.588+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "fraud-exposure" } ], "arcBeats": [ { "to": 11, "arc": { "name": "Overcoming the Monster", "slug": "overcoming-monster", "status": "active", "bestFor": "Competitive positioning, rallying teams", "canonId": "019dd956-6339-76ac-9cbf-4b377c3aa89e", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "The Monster -> The Call -> The Struggle -> The Victory -> The New Order", "description": null, "familyLabel": null }, "from": 10, "name": "Villain Critique", "beatId": "17111959-043c-4444-914f-d47e7b87f2ca", "matchId": "b8ffb429-a2f5-4e23-8c7d-3083a9a8ae39", "beatType": null, "evidence": "The document critiques Pulse Biosciences' leadership and market claims, portraying them as weak and unstable.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1ef62e8b-adc1-441c-a66b-e6fcf4ca1475", "evidence": "The document implies that investors who do not take action to address Pulse Biosciences' challenges will suffer financial losses.", "position": 1, "objective": "To highlight the cost of inaction for investors", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:02:00.078667+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "setup", "title": "The slide uses a narrative style to critique management and predict future failure based on historical precedents.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 5, "textChars": 506, "nDataPoints": 3, "notes": "The slide uses a narrative style to critique management and predict future failure based on historical precedents.", "elementsJson": [ "logo_grid", "paragraph" ], "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:08:59.151+00", "seconds": 2.961, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/12", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-12", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Given PLSE's weak initial clinical data in thyroids, we predict a forthcoming commercial failure, inevitably leading to another PLSE stock crash like what happened in 2021 when its dermatology application failed.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-23 02:33:30+00", "model": "unknown-legacy", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd953-70fa-7556-8663-d251ff5a27f5", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.08, "y": 0.07 }, "kind": "image", "text": "White Diamond Research", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.151+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "26ccf0b5-4c5c-4f15-b0e1-f54e409f3ae9", "parentComponentId": null }, { "bbox": { "h": 0.42, "w": 0.84, "x": 0.08, "y": 0.14 }, "kind": "paragraph", "text": "Danahy didn't understand how to deal with the FDA... Since Danahy failed, they brought in Barrett... Finally, they appointed LaViolette...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.151+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5856653f-9d55-4085-826c-26ef4c30f9f4", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.84, "x": 0.08, "y": 0.64 }, "kind": "paragraph", "text": "PLSE's NPS technology has a long history of commercial failures which contradict the company's sky-high valuation of $1B+...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.151+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9421e911-bdd6-4c70-950e-6618d0b46397", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.08, "y": 0.59 }, "kind": "title", "text": "Conclusion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:08:59.151+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f76d85fc-1e26-4768-9632-fe7e6d8d01ba", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7164b58e-3007-4ad6-be9e-97cf8c9cf0d4", "evidence": "This slide contains a summary of the key points, making it an executive summary.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:11:38.571061+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "setup", "function": "filler", "rawType": "filler", "block": null, "metadata": { "slideType": "filler", "slideTypeCanon": { "name": "Filler", "slug": "filler", "status": "active", "canonId": "019de52d-0829-76f9-9abe-4c11ee7bf4ab", "version": 1, "description": null }, "function": "filler", "functionCanon": { "name": "Filler", "slug": "filler", "status": "active", "canonId": "019de52d-1568-702b-ad12-428490978783", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 55, "nDataPoints": 0, "notes": null, "elementsJson": [ "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 20:09:00.122+00", "seconds": 3.716, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-622c-750b-8b9a-cb61f3b5c0ba/13", "deck": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba", "deckAnchor": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba#slide-13", "deckJson": "/decks/019dd923-622c-750b-8b9a-cb61f3b5c0ba.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.23, "x": 0.08, "y": 0.07 }, "kind": "image", "text": "WHITE DIAMOND RESEARCH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:00.122+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f62185a7-83e8-4de7-85bf-4b1fc9e4cdab", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.08, "y": 0.97 }, "kind": "paragraph", "text": "https://whitediamondresearch.com/", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 20:09:00.122+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b577a42a-eb7d-44d8-87cd-fe69e80e13ce", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 2, "to": 5, "label": "Expose Contradiction", "description": "The document presents contradictory information about Pulse Biosciences, such as its competitor Kardium's success and Dr. Vivek Reddy's statement about the advantage of nano-second PFA." }, { "from": 7, "to": 7, "label": "Preempt Rebuttal", "description": "The document preempts potential rebuttals by discussing Farapulse's prior research and its implications for Pulse Biosciences." }, { "from": 10, "to": 11, "label": "Villain Critique", "description": "The document critiques Pulse Biosciences' leadership and market claims, portraying them as weak and unstable." } ], "loops": [ { "from": 2, "to": 5, "label": "Pattern Hunter", "description": "To identify patterns in Pulse Biosciences' failure and weakness" }, { "from": 10, "to": 11, "label": "Cost Of Inaction", "description": "To highlight the cost of inaction for investors" } ] }